Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Centessa Pharmaceuticals Plc ADR (NQ: CNTA ) 9.870 +0.470 (+5.00%) Streaming Delayed Price Updated: 4:00 PM EDT, Jul 23, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Centessa Pharmaceuticals Plc ADR < Previous 1 2 3 Next > Centessa Pharmaceuticals Strengthens Executive Leadership with Appointment of John Crowley CPA, as Chief Financial Officer and Gregory Weinhoff MD MBA, as Chief Business Officer June 10, 2024 From Centessa Pharmaceuticals plc Via GlobeNewswire Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences May 21, 2024 From Centessa Pharmaceuticals plc Via GlobeNewswire Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2024 May 13, 2024 From Centessa Pharmaceuticals plc Via GlobeNewswire Centessa Pharmaceuticals Announces Pricing of $100 Million Public Offering of American Depositary Shares April 23, 2024 From Centessa Pharmaceuticals plc Via GlobeNewswire Centessa Pharmaceuticals Announces $100 Million Proposed Public Offering of American Depositary Shares April 23, 2024 From Centessa Pharmaceuticals plc Via GlobeNewswire Centessa Pharmaceuticals Announces Open IND for ORX750; Proof-of-Concept Data in Sleep-Deprived Healthy Volunteers Planned for 2H 2024 April 22, 2024 From Centessa Pharmaceuticals plc Via GlobeNewswire Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2023 March 28, 2024 From Centessa Pharmaceuticals plc Via GlobeNewswire Centessa Pharmaceuticals to Participate in TD Cowen’s 44th Annual Health Care Conference February 22, 2024 From Centessa Pharmaceuticals plc Via GlobeNewswire Centessa Pharmaceuticals to Present Additional 52-Weeks of Continuous Treatment Data from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia at the 17th Annual Congress of the European Association for Haemophilia and February 09, 2024 From Centessa Pharmaceuticals plc Via GlobeNewswire Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences January 22, 2024 From Centessa Pharmaceuticals plc Via GlobeNewswire Centessa Pharmaceuticals to Present at the 42ⁿᵈ Annual J.P. Morgan Healthcare Conference December 13, 2023 From Centessa Pharmaceuticals plc Via GlobeNewswire Centessa Pharmaceuticals Announces New Data from an Additional 52-Weeks of Continuous Treatment from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia December 10, 2023 From Centessa Pharmaceuticals plc Via GlobeNewswire Anaptys Expands Immune Cell Modulator Pipeline with Exclusive License to BDCA2 Modulator Antibody Portfolio from Centessa Pharmaceuticals November 27, 2023 From AnaptysBio, Inc. Via GlobeNewswire Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Third Quarter of 2023 November 13, 2023 From Centessa Pharmaceuticals plc Via GlobeNewswire Centessa Pharmaceuticals to Present Additional 52-Weeks of Continuous Treatment Data from Third Year of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia at American Society of Hematology (ASH) Annual Meeting November 02, 2023 From Centessa Pharmaceuticals plc Via GlobeNewswire Centessa Pharmaceuticals Announces Dosing of First Subject in Registrational PRESent-3 Study Evaluating SerpinPC for the Treatment of Hemophilia B with Inhibitors October 31, 2023 From Centessa Pharmaceuticals plc Via GlobeNewswire Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences October 30, 2023 From Centessa Pharmaceuticals plc Via GlobeNewswire Centessa Pharmaceuticals Announces Preclinical Data Supporting ORX750’s Potential as a Best-in-Class Oral OX2R Agonist for the Treatment of Narcolepsy and Other Sleep-Wake Disorders October 25, 2023 From Centessa Pharmaceuticals plc Via GlobeNewswire Centessa Pharmaceuticals Announces Additions to Senior Leadership Team October 03, 2023 From Centessa Pharmaceuticals plc Via GlobeNewswire Centessa Pharmaceuticals to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference August 31, 2023 From Centessa Pharmaceuticals plc Via GlobeNewswire Centessa Pharmaceuticals to Present Preclinical Data for Novel Orexin Receptor 2 (OX2R) Agonist at World Sleep Congress August 23, 2023 Oral presentation to include preclinical profile for ORX750, Centessa’s first orexin agonist development candidate for the treatment of narcolepsy and other sleep disorders From Centessa Pharmaceuticals plc Via GlobeNewswire Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2023 August 14, 2023 From Centessa Pharmaceuticals plc Via GlobeNewswire Centessa Pharmaceuticals Announces Dosing of First Subject in Registrational PRESent-2 Study Evaluating SerpinPC for the Treatment of Hemophilia B without Inhibitors July 10, 2023 Enrollment progressing toward interim analysis planned when 36 subjects reach 12 weeks on treatment in Part 1 of study From Centessa Pharmaceuticals plc Via GlobeNewswire Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences May 24, 2023 From Centessa Pharmaceuticals plc Via GlobeNewswire Centessa Pharmaceuticals Receives Fast Track Designation from the U.S. FDA for SerpinPC for Hemophilia B May 22, 2023 From Centessa Pharmaceuticals plc Via GlobeNewswire Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2023 May 12, 2023 From Centessa Pharmaceuticals plc Via GlobeNewswire Centessa Pharmaceuticals Reports Recent Business Progress and Financial Results for the Fourth Quarter and Full-Year 2022 March 30, 2023 From Centessa Pharmaceuticals plc Via GlobeNewswire Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences March 27, 2023 From Centessa Pharmaceuticals plc Via GlobeNewswire Centessa Pharmaceuticals Announces Addition of Patrick Yue, MD, as Senior Vice President of Clinical Development, Innovative Medicines March 01, 2023 From Centessa Pharmaceuticals plc Via GlobeNewswire Centessa Pharmaceuticals Plc (NASDAQ:CNTA) Long Term Shareholder Notice: Investigation of Potential Wrongdoing February 14, 2023 San Diego, CA -- (SBWIRE) -- 02/14/2023 -- An investigation was announced for investors in shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA) concerning potential breaches of fiduciary duties by... Via SBWire < Previous 1 2 3 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.